Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Systemic Lupus Erythematosus
Interventions: CO-LEAD; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Neoplasms
Interventions: Not listed
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 100 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Breast Cancer
Interventions: goserelin, letrozole, leuprolide acetate, conventional surgery; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Dermatitis
Interventions: PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%, Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%, Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%, Silwet* DA-63 (Momentive) 1.5%, Sodium lauryl sulfate (Sigma Aldrich) 1.0%, Water (control); Other
Lead sponsor: Kimberly-Clark Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Irving, Texas

Conditions: Wrinkle, Fine Lines, Crepey Skin, Acne Scars, Active Acne, Enlarged Pores, Stretch Mark, Loose Skin
Interventions: RadioFrequency Microneedling Device; Device
Lead sponsor: Cynosure, Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Westford, Massachusetts

Conditions: Metastatic Melanoma
Interventions: Masitinib, Dacarbazine; Drug
Lead sponsor: AB Science; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Breast Cancer
Interventions: Doxorubicin, Cyclophosphamide, Paclitaxel, Sorafenib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 8
States / cities: Jacksonville, Florida • Orlando, Florida • Louisville, Kentucky + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Relaxation response and cognitive behavioral therapy, Relaxation response, RA education; Behavioral · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Tin ethyl etiopurpurin; Drug
Lead sponsor: Clinical Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 2 more

Conditions: Breast Cancer, Insomnia
Interventions: PROSPECT; Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Early-Stage Breast Cancer
Interventions: Proton radiation therapy; Radiation
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Hidradenitis Suppurativa (HS)
Interventions: AviClear Lase Treatment, Sham (No Treatment); Device
Lead sponsor: Wynn Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rosemead, California

Conditions: Diabetes, Breast Cancer
Interventions: Integrated Intervention for Breast Cancer Survivors with Diabetes, Attention Control; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 55 Years and older · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Chicago, Illinois • New Hyde Park, New York • New York, New York

Conditions: Breast Cancer
Interventions: Trastuzumab; Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Degeneration; Articular Cartilage, Knee, Rheumatoid Arthritis, Osteoarthritis, Knee
Interventions: Clinic-based outpatient exercise group, Community-based exercise group; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Allergic Contact Dermatitis, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions: Sylke Adhesive Dressing, Exofin Skin Glue, Suture Strip Plus; Procedure
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Systemic Sclerosis (SSc)
Interventions: Apollo Neuro Device, Sham device; Device
Lead sponsor: Robyn T. Domsic, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: New Orleans, Louisiana • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more

Conditions: Pressure Ulcers
Interventions: Envision® Patient Support System; Device
Lead sponsor: Hill-Rom; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Tilmanocept, Sulfur Colloid; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Premature Birth
Interventions: Adhesive and non-adhesive oximetry sensors; Device
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Up to 2 Weeks
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hidradenitis Suppurativa
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ductal Carcinoma In Situ, Breast Cancer
Interventions: Active Comparator: Progressive Resistance Training (PRT) and a healthy diet, Experimental: PRT and a healthy diet, plus weight loss; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2%, Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Fountain Valley, California • Fremont, California • Colorado Springs, Colorado + 20 more

Conditions: Ecchymosis
Interventions: Arnica montana, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 89 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Intervention to Improve Communication and Medication Adherence in Lupus

Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer

Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer

A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants

Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

Relaxation Response Training for the Treatment of Rheumatoid Arthritis

Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.

Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer

Proton Therapy for Early Stage Breast Cancer

1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)

Integrated Intervention for Breast Cancer Survivors With Diabetes

Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer

Comparison of Treatments Following Total Knee Replacement

Rate of Allergic Contact Dermatitis and Cosmetic Outcomes

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

A Pilot Study of the Envision® Surface

Sentinel Lymph Node Mapping Post-Injection Site Pain

Evaluation of Pulse Oximetry Sensors in Neonates

Clinical and Biological Characteristics of Hidradenitis Suppurativa

Effects of Diet and Exercise on Ductal Carcinoma in Situ

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery